Lv4
530 积分 2026-10-01 加入
Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting
10天前
已完结
Decoding BRCA1 and BRCA2 mutations: implications of mutation type and domain location for PARP inhibitor response in ovarian cancer
10天前
已完结
Perspectives on Homologous Recombination Repair Deficiency (HRD)
10天前
已完结
Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors
10天前
已完结
Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types
10天前
已完结
Assessment of Homologous Recombination Deficiency in Ovarian Cancer
10天前
已完结
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
10天前
已完结
A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma (2271)
10天前
已关闭
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)
10天前
已完结
779P Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
10天前
已完结